Gerresheimer: 160 Years of Corporate History — and One Paragraph in the Auditor's Report That Changes Everything

There is an investor weakness that works far more quietly than greed: trust in age. A company that has existed since 1864, whose vials sit in every medicine cabinet and whose name has been on an exchange for decades, surely cannot get into real trouble — the thought arrives almost by itself, which is why hardly anyone checks. So let us make a deal: we will read Gerresheimer AG's (Xetra: GXI) Annual Report 2025 together all the way to the end — including the part nobody reads, the independent auditor's report. Since June 29, 2026 it has contained a section of its own, headed "Material Uncertainty about the Ability to Continue as a Going Concern."

That names the central tension of this analysis, and it runs through every chapter: the operating business is real, it has grown, and it sits in a market that is growing — but the balance sheet above it has become so heavy that the auditor was no longer willing to sign off on the company's continuation without a warning. And the way out that management has found consists of selling the highest-margin piece.

What Gerresheimer Actually Does

Gerresheimer is not a pharmaceutical company; it is the supplier no pharmaceutical company can do without. The group, headquartered in Duesseldorf, describes itself in the annual report as a systems and solutions provider to the pharma, biotech and cosmetics industries. Translated into everyday terms: if a drug is the content, Gerresheimer builds the packaging, the dosing aid and the device that gets the content into a human being.

The portfolio ranges from injection vials, cartridges and ampoules through tablet containers and infusion, dropper and syrup bottles to syringes, pens, autoinjectors, inhalers and drug pumps. As of November 30, 2025, 13,528 people worked there (prior year: 12,142). The fiscal year does not end on December 31 but on November 30 — fiscal 2025 therefore covers December 1, 2024 through November 30, 2025. Anyone comparing Gerresheimer quarters with those of other suppliers is comparing shifted periods.

From fiscal 2026 the group reports in three divisions: Containment & Delivery Systems (comprising Primary Packaging Plastics, Centor, Medical Systems and Advanced Technologies), Primary Injectable Solutions and Moulded Glass. That structure matters immediately — because the sale now underway comes out of the first and largest of the three.

How the Stock Landed on Our Desk

No scanner hook this time, but other people's attention: on August 4, 2026 Gerresheimer appeared on the wallstreet-online forum ranking of the most discussed stocks among German retail investors. That is not a buy signal; it is a sign that a lot of people have the same question — and for a company that had to postpone its annual accounts three times, dropped out of the SDAX index and then produced two versions of the same consolidated statements within four weeks, the question is an obvious one.

The shares trade in the Prime Standard segment of the Frankfurt Stock Exchange (ISIN DE000A0LD6E6). With around 34.54 million shares outstanding, market capitalization as of the August 4, 2026 data date was in the region of just under EUR 1 billion — roughly 0.4 times annual revenue and about 0.9 times book value. Ratios like that look cheap. Whether they are depends on whether book value holds. That is what the rest of this analysis is about.

The Numbers Over the Years — What Genuinely Impresses

Start with what is actually good. Revenue has risen more or less without interruption over five years: from EUR 1,498.0 million (2021) through EUR 1,817.1 million (2022), EUR 1,983.2 million (2023) and EUR 1,991.3 million (2024, restated) to EUR 2,320.9 million in fiscal 2025 — up 16.6 percent, and 17.8 percent on a currency-adjusted basis to EUR 2,361.9 million. The main driver was the Bormioli Pharma acquisition. Headcount grew from 10,447 (2021) to 13,528.

And the market behind it is no fad. The annual report expects volume-based growth in biopharmaceuticals averaging 4.1 percent a year from 2025 to 2030, and 5.1 percent in North America. If you make syringes and autoinjectors for biologic drugs, you are structurally on the right side of that trend.

Except that revenue is one line. The chart below shows the other.

Up to that point the earnings per share series reads calmly: EUR 2.67 (2021), EUR 3.06 (2022), EUR 3.31 (2023), EUR 2.37 (2024, restated) — and then minus EUR 9.27 in fiscal 2025.

Fiscal 2025 ended with a net loss of EUR 318.7 million after a profit of EUR 84.3 million in the restated prior year. Even on an adjusted basis — excluding one-off effects, amortization on purchase price allocations and restructuring — a loss of EUR 63.0 million remained, against a profit of EUR 140.8 million a year earlier. Adjusted EBITDA, the group's preferred operating measure, slipped from EUR 388.0 million to EUR 384.0 million; because revenue rose sharply at the same time, the adjusted EBITDA margin fell from 19.5 to 16.5 percent. No dividend is proposed for fiscal 2025; the prior year paid EUR 0.04 per share — after EUR 1.25 in each of the three years before that.

That combination — revenue up, earnings down — is familiar from other work of ours: at Standard Motor Products a large acquisition story lifted revenue by 22 percent without the income statement following. The difference here is the balance sheet underneath, and that is where we go next.

Uncomfortable Truth No. 1: The Auditor Writes About Continuation

An auditor's report is normally a form. The auditor confirms that the accounts comply with the rules, and that is that. When an additional section shows up, it is not a formality but a message. In the Annual Report 2025, KPMG did exactly that.

"… these events and conditions indicate material uncertainty that could cast significant doubt on the ability of Gerresheimer AG as Parent Company and on the ability of the Gerresheimer Group to continue as a going concern and which represent a going concern risk within the meaning of Section 322 (2) sentence 3 HGB."

— KPMG AG Wirtschaftsprüfungsgesellschaft, Gerresheimer AG, Annual Report 2025, Independent Auditor's Report (revised version dated July 23, 2026)

What does that mean in plain language? A set of annual accounts is normally prepared on the assumption that the company will still exist next year — accountants call it the going concern assumption. Every value in the balance sheet rests on it: machines are carried at what they are worth in ongoing operations, not at what a forced sale would fetch. When the auditor says there is material uncertainty about that assumption, the plain reading is: the numbers in this book hold only if a number of things go right.

Important for the record, in both directions: the auditor did not withhold the opinion. It states explicitly that the assumptions made by the Management Board and the presentation in the notes are reasonable, and that the audit opinions were not modified in this regard. The Management Board considers the going concern assumption appropriate — chiefly because the plans show sufficient headroom against the contractual limits given expected operating performance, and because the sale of Centor is expected. So this kind of paragraph is not an insolvency filing. It is a documented statement, shared by the statutory auditor, that the substance depends on conditions.

Uncomfortable Truth No. 2: The Covenant Calendar Runs Out

Which conditions those are appears a few chapters earlier. There are two credit conditions — covenants. A covenant is a promise to the lender: as long as a given metric stays inside the agreed limit, the loan runs on. Break the limit, and the bank may call the loan.

The chart shows two series that moved in parallel for years and then diverged. Net financial debt stood at EUR 1,025.1 million (2021), EUR 1,112.6 million (2022), EUR 924.3 million (2023) and EUR 1,100.3 million (2024, restated) — four years inside a narrow band. Over the same period equity climbed from EUR 1,014.7 million through EUR 1,269.4 million and EUR 1,465.2 million to EUR 1,504.8 million. In fiscal 2025 both tip at once: debt to EUR 2,012.9 million, equity to EUR 1,107.1 million.

The decisive metric is adjusted EBITDA leverage, the ratio of net financial debt to operating earnings of the last twelve months. Put simply: how many years of earnings would the company need to pay off its debt? As of November 30, 2024 the answer was 2.61 — as of November 30, 2025 it was 4.95. Over the same period net financial debt rose from EUR 1,100.3 million to EUR 2,012.9 million, as financial debt climbed from EUR 1,286.7 million to EUR 2,189.1 million while cash fell from EUR 186.4 million to EUR 176.2 million.

"Gerresheimer is not required to comply with any financial covenants as of the reporting dates November 30, 2025, February 28, 2026, May 31, 2026 and August 31, 2026. As of November 30, 2026, the financial covenant, based on adjusted EBITDA leverage, may not exceed 4.75x."

— Gerresheimer AG, Annual Report 2025, Report on the Economic Position

Work it through soberly. Actual value at the last reporting date: 4.95. Permitted value at November 30, 2026: 4.75 at most. The gap is 0.20 points — and it has to be closed within a fiscal year in which the group itself expects a free cash outflow of EUR 50 million to EUR 100 million. There are exactly two levers: operating earnings must rise, or debt must fall. The Apax sale is the second lever, and we come to it shortly.

On top of that sits the second condition, which gets less attention and may well bite sooner: a liquidity covenant requiring minimum liquidity of EUR 100.0 million, tested at least monthly. The annual report is blunt about what a breach would mean: a violation of the financial covenant or the liquidity covenant may lead the participating lenders to accelerate the obligations — which applies indirectly to the term loans as well.

A line worth keeping: a covenant is not a risk in the future; it is a date in the calendar. The next one reads November 30, 2026.

Uncomfortable Truth No. 3: BaFin Twice — and EUR 44.6 Million of Revenue That Was Not There

In September 2025 the German financial regulator BaFin opened an examination of the published consolidated financial statements as of November 30, 2024. The subject: orders for which so-called bill and hold agreements totaling EUR 28 million were concluded with customers in the final third of fiscal 2024. Bill and hold means the customer buys the goods but they stay in the seller's warehouse for the time being. The question is then whether revenue may already be booked.

"The first subject of the audit concerns revenue recognition from bill and hold agreements totaling approximately EUR 28m. An audit by an independent law firm revealed that the requirements for revenue recognition were not met."

— Gerresheimer AG, Annual Report 2025, Corporate Governance Statement

The consequence was a retroactive error correction under accounting standard IAS 8: prior-year revenue fell by a total of EUR 44.6 million. That is why the comparative figures for 2021, 2023 and 2024 in the Annual Report 2025 carry the word "restated" — the numbers investors read in earlier years were in part different from the ones that apply today.

It did not stop at one examination. In March 2026 BaFin opened a second special examination, this time of the interim accounts as of May 31, 2025, and simultaneously extended the ongoing examination of fiscal 2024 to three further points: the presentation of lease liabilities, the useful lives of capitalized development costs, and the recoverability of the assets of the Advanced Technologies division. Neither examination was concluded when the accounts were prepared. After the examination was opened, Gerresheimer commissioned an external, independent law firm and a second audit firm to carry out independent investigations.

Uncomfortable Truth No. 4: The Accounts Had to Be Prepared Twice

The 2025 consolidated financial statements were prepared by the Management Board and approved by the Supervisory Board on June 29, 2026. Four weeks later they were no longer the valid ones.

"After the consolidated financial statements were originally prepared by the Management Board and approved by the Supervisory Board on June 29, 2026, the Management Board reviewed them and restated them in amended form on July 23, 2026."

— Gerresheimer AG, Annual Report 2025, page 2 and note (1) "General Information"

Precision matters more than drama here, so the finding in plain terms: the amendments related exclusively to the presentation and disclosure of segment information — specifically the allocation of an impairment loss to goodwill and the correction of carryover errors in the reconciliation of the segments' adjusted EBITDA to consolidated net income. The report states expressly that this had no impact on the group's financial position, results of operations, or cash flows. The auditor conducted a supplementary audit and amended the auditor's report accordingly; the Supervisory Board approved the amended accounts on July 23, 2026 and found no objections.

So the numbers did not move. What it does show is something else: a group that had already filed its annual accounts months late then needed a second attempt to get the segment presentation right. Anyone assessing the reliability of the reporting should know about this episode — and anyone inflating it into a scandal has not read the report.

What Changed on July 29, 2026: The Apax Sale

Six days after the second preparation came the news that shifts the picture. On July 29, 2026 Gerresheimer announced, via ad-hoc release, definitive agreements with an affiliate of funds advised by Apax Partners LLP to sell Centor US Holding Inc. and the global Primary Packaging Plastics business.

The key terms from the release: the purchase price is based on a combined enterprise value of approximately EUR 1.5 billion. Besides the Centor site in the United States, the transaction covers a total of 15 production sites for primary plastic packaging in nine countries — 16 sites in all, with around 2,400 employees and combined revenue of roughly EUR 570 million in 2025. The Centor sale is expected to close by the end of fiscal 2026, the plastics business in the first half of fiscal 2027. Both transactions are subject to customary closing conditions and approvals and will close independently of one another.

CEO Uwe Röhrhoff calls it regaining "strategic flexibility"; CFO Wolf Lehmann says the expected cash inflows will be used to accelerate debt reduction and, together with a planned comprehensive refinancing, to reduce interest expense significantly. Measured against the starting position, that is the plausible route — EUR 1.5 billion of enterprise value stands against EUR 2,012.9 million of net financial debt.

Three things belong beside it nonetheless. First: what is being sold comes out of Containment & Delivery Systems, the division with the highest margin — a pro forma adjusted EBITDA margin of 22.9 percent on EUR 1,172 million of 2025 revenue, against 15.3 percent at Primary Injectable Solutions and 12.8 percent at Moulded Glass. Deleveraging by disposal is not a free move: it also shrinks the earnings against which leverage is measured. Second: the fiscal 2026 guidance in the annual report is expressly stated before M&A and refinancing activities — it does not yet reflect the sale. Third: a contract is not a cash receipt. Until closing, the balance sheet is what it is.

What the Stock Costs

Deliberately as an order of magnitude and explicitly dated, because daily prices are not an argument: with around 34.54 million shares outstanding, market capitalization as of the August 4, 2026 data date was just under EUR 1 billion. That implies a price-to-sales ratio of roughly 0.4 on 2025 revenue of EUR 2,320.9 million and a price-to-book ratio of about 0.9 on equity of EUR 1,107.1 million as of November 30, 2025. A price-to-earnings ratio cannot be formed — 2025 was a loss year.

The more meaningful measure here is enterprise value, market capitalization plus net debt: it sits in the region of EUR 2.9 billion, roughly seven times adjusted EBITDA of EUR 384.0 million. Put differently: economically, two thirds of this company belongs to the creditors, not the shareholders. That is precisely why the share price depends unusually heavily on the balance sheet and unusually little on revenue — anyone looking only at the price-to-sales ratio of a heavily indebted company is measuring the wrong slice.

For fiscal 2026, and before disposals and refinancing, Gerresheimer expects revenue in the lower half of the EUR 2,300 million to EUR 2,400 million range, an adjusted EBITDA margin of around 17 to 18 percent, and free cash flow of minus EUR 50 million to minus EUR 100 million. All three were cut in June 2026; the previous guidance was an 18 to 19 percent margin and a "moderately positive" cash inflow.

Opportunities and Risks at a Glance

Opportunities

• The end market grows structurally: the annual report expects volume-based growth in biopharmaceuticals averaging 4.1 percent a year to 2030, and 5.1 percent in North America. Syringes, pens and autoinjectors for biologic drugs are the right side of that trend.
• The Apax sale is signed, not merely planned: roughly EUR 1.5 billion of enterprise value against EUR 2,012.9 million of net financial debt — a deleveraging step of the right order of magnitude, with Centor closing expected by the end of fiscal 2026.
• Operationally the base is intact: EUR 2,320.9 million of revenue (2025), EUR 384.0 million adjusted EBITDA, EUR 209.5 million of operating cash flow and 13,528 employees. Capital expenditure for 2026 is planned well below the prior year (2025: EUR 308.3 million in cash terms).
• The valuation already carries a lot of skepticism: roughly 0.4 times annual revenue and about 0.9 times book value (data as of August 4, 2026). If deleveraging succeeds, the leverage works in both directions.

Risks

• The auditor's report identifies a going concern risk within the meaning of Section 322 (2) sentence 3 HGB. That is not sentiment; it is an audited finding.
• The November 30, 2026 date: leverage has to come back from 4.95x to no more than 4.75x, while a liquidity covenant of EUR 100.0 million is tested at least monthly. A breach may trigger acceleration — indirectly for the term loans too.
• The maturity wall: EUR 881.5 million of financial debt falls due in fiscal 2027 and EUR 1,021.5 million in fiscal 2029; the Bormioli Pharma bridge loan stood at EUR 525.0 million at the reporting date and runs to September 2027.
• Two BaFin examinations were unfinished when the accounts were prepared. The outcome is open; the report says expenses or income above or below the provisions recognized cannot be ruled out.
• Management explicitly does not rule out further impairment losses to be recognized in the 2026 Half-Year Financial Report — against equity that has already fallen from EUR 1,504.8 million to EUR 1,107.1 million.
• The company's own 2026 guidance calls for a free cash outflow of EUR 50 million to EUR 100 million, partly because the financial partners cut the factoring volumes.

A Human Conclusion

We started with trust in age — with the feeling that a name dating from 1864 comes with a kind of airbag. The Annual Report 2025 shows what that airbag is worth: it holds the business, but not the balance sheet. Gerresheimer still makes products that are needed, in a market that is growing, with 13,528 people and EUR 2.3 billion of revenue. And in the very same book sits a paragraph a statutory auditor only writes when there is no alternative.

What follows from that is not a recommendation but a structure: this stock is not a bet on syringes and vials. It is a bet on a calendar — on closing the Centor sale by the end of fiscal 2026, on leverage below 4.75x at November 30, 2026, on a refinancing ahead of the EUR 881.5 million wall in fiscal 2027. If the calendar works out, a valuation of roughly 0.4 times revenue will look in hindsight like the entry point. If it does not, the outcome is decided not by margin but by a bank.

Anyone who reads this analysis and says "too uncertain" has understood the report correctly. Anyone who says "precisely for that reason" has understood it correctly too — with a different appetite for risk. Both are legitimate. What would not be legitimate is skipping the paragraph on the closing pages because the name sounds so familiar. What you do with it is your decision. And that is exactly as it should be.

More deep dives are collected in our research section.

Sources

• Gerresheimer AG — Annual Report 2025 (English edition, 163 pages), published June 29, 2026, revised version dated July 23, 2026: independent auditor's report, report on the economic position, forecast report, corporate governance statement, notes (1), (3) and (17), subsequent events, Five-Year Overview (page 162). The reports page marks the file as "Revised version as of July 23, 2026."
• Gerresheimer AG — Geschäftsbericht 2025 (German edition), the authoritative original of the German-language passages
• Gerresheimer AG — corporate news: "Gerresheimer is selling Centor and its global Primary Packaging Plastics business to Apax Funds", July 29, 2026
• Gerresheimer AG — ad-hoc announcements, including July 29, 2026 (sale of Centor and Primary Packaging Plastics) and June 2026 (publication of the 2025 annual accounts, annual general meeting on September 1, 2026, adjustment of the 2026 guidance)
• Gerresheimer AG — financial calendar, as of August 4, 2026: annual general meeting September 1, 2026, half-year financial report September/October 2026, third-quarter statement October 2026
• Fundamental data: market capitalization, share count, trailing twelve-month ratios; data as of August 4, 2026

This analysis is journalistic commentary based on publicly available documents. It is not investment advice, not a solicitation to buy or sell securities, and not a personal recommendation. Shares can lose substantial value, and a total loss of the capital invested is possible. Every figure carries the reporting date of its source; market data carry the August 4, 2026 data date and may have changed since. The author holds no position in Gerresheimer AG at the time of publication.